News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
835,739 Results
Type
Article (85888)
Company Profile (649)
Press Release (749202)
Section
Business (232122)
Career Advice (4122)
Deals (39701)
Drug Delivery (124)
Drug Development (90733)
Employer Resources (196)
FDA (17964)
Job Trends (17303)
News (395351)
Policy (39632)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (7)
2025 Lone Star Bio Digital (8)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2983)
Academic (1)
Accelerated approval (3)
Adcomms (25)
Allergies (74)
Alliances (56591)
ALS (69)
Alzheimer's disease (1420)
Antibody-drug conjugate (ADC) (117)
Approvals (17947)
Artificial intelligence (198)
Autoimmune disease (14)
Automation (10)
Bankruptcy (400)
Best Places to Work (12511)
BIOSECURE Act (21)
Biosimilars (107)
Biotechnology (447)
Bladder cancer (51)
Brain cancer (25)
Breast cancer (198)
Cancer (1658)
Cardiovascular disease (114)
Career advice (3524)
Career pathing (32)
CAR-T (143)
Cell therapy (405)
Cervical cancer (14)
Clinical research (72389)
Collaboration (678)
Compensation (354)
Complete response letters (27)
COVID-19 (2819)
CRISPR (38)
C-suite (176)
Cystic fibrosis (97)
Data (1518)
Decentralized trials (2)
Denatured (42)
Depression (34)
Diabetes (163)
Diagnostics (6714)
Digital health (8)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (104)
Drug pricing (90)
Drug shortages (17)
Duchenne muscular dystrophy (61)
Earnings (94830)
Editorial (32)
Employer branding (25)
Employer resources (167)
Events (127677)
Executive appointments (519)
FDA (18750)
Featured Employer (65)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (559)
Gene editing (89)
Generative AI (21)
Gene therapy (282)
GLP-1 (702)
Government (5069)
Grass and pollen (3)
Guidances (32)
Healthcare (20731)
Huntington's disease (24)
IgA nephropathy (22)
Immunology and inflammation (102)
Indications (21)
Infectious disease (2917)
Inflammatory bowel disease (142)
Inflation Reduction Act (11)
Influenza (36)
Intellectual property (68)
Interviews (811)
IPO (17671)
IRA (38)
Job creations (5183)
Job search strategy (2860)
Kidney cancer (10)
Labor market (33)
Layoffs (516)
Leadership (18)
Legal (10043)
Liver cancer (69)
Lung cancer (246)
Lymphoma (112)
Machine learning (2)
Management (65)
Manufacturing (244)
MASH (58)
Medical device (14278)
Medtech (14283)
Mergers & acquisitions (22205)
Metabolic disorders (530)
Multiple sclerosis (61)
NASH (22)
Neurodegenerative disease (78)
Neuropsychiatric disorders (23)
Neuroscience (1841)
NextGen: Class of 2025 (7663)
Non-profit (5054)
Northern California (2006)
Now hiring (37)
Obesity (290)
Opinion (262)
Ovarian cancer (57)
Pain (57)
Pancreatic cancer (53)
Parkinson's disease (112)
Partnered (15)
Patents (159)
Patient recruitment (73)
Peanut (47)
People (64625)
Pharmaceutical (131)
Pharmacy benefit managers (13)
Phase I (22355)
Phase II (31472)
Phase III (23666)
Pipeline (764)
Podcasts (117)
Policy (105)
Postmarket research (3542)
Preclinical (10022)
Press Release (72)
Prostate cancer (72)
Psychedelics (34)
Radiopharmaceuticals (247)
Rare diseases (326)
Real estate (7377)
Recruiting (75)
Regulatory (26245)
Reports (52)
Research institute (2642)
Resumes & cover letters (649)
Rett syndrome (1)
RNA editing (2)
RSV (30)
Schizophrenia (63)
Series A (111)
Series B (60)
Service/supplier (25)
Sickle cell disease (43)
Southern California (1718)
Special edition (18)
Sponsored (33)
Startups (4279)
State (2)
Stomach cancer (11)
Supply chain (43)
The Weekly (74)
United States (17558)
Vaccines (693)
Venture capitalists (34)
Webinars (13)
Weight loss (215)
Women's health (33)
Worklife (17)
Date
Today (38)
Last 7 days (471)
Last 30 days (2418)
Last 365 days (30989)
2025 (5384)
2024 (34033)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1264)
Alabama (49)
Alaska (6)
Arizona (230)
Arkansas (8)
Asia (49635)
Australia (8764)
California (4587)
Canada (1432)
China (405)
Colorado (150)
Connecticut (197)
Delaware (108)
Europe (113578)
Florida (563)
Georgia (125)
Hawaii (1)
Idaho (64)
Illinois (409)
India (21)
Indiana (249)
Iowa (7)
Japan (110)
Kansas (106)
Kentucky (16)
Louisiana (7)
Maine (58)
Maryland (764)
Massachusetts (3668)
Michigan (174)
Minnesota (290)
Mississippi (1)
Missouri (49)
Montana (24)
Nebraska (26)
Nevada (49)
New Hampshire (49)
New Jersey (1325)
New Mexico (27)
New York (1299)
North Carolina (932)
North Dakota (7)
Northern California (2006)
Ohio (149)
Oklahoma (12)
Oregon (44)
Pennsylvania (981)
Puerto Rico (7)
Rhode Island (19)
South America (1646)
South Carolina (3)
South Dakota (1)
Southern California (1718)
Tennessee (28)
Texas (602)
Utah (104)
Virginia (85)
Washington D.C. (35)
Washington State (466)
West Virginia (1)
Wisconsin (35)
835,739 Results for "2seventy bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
March 11, 2025
·
3 min read
·
Tristan Manalac
Press Releases
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
March 11, 2025
·
19 min read
Press Releases
2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference
February 25, 2025
·
1 min read
Press Releases
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
February 6, 2025
·
18 min read
Cell Therapy
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told
BioSpace
transparency and a committed staff have kept the biotech going through thick and thin.
October 2, 2024
·
8 min read
·
Annalee Armstrong
Genetown
2seventy bio to Participate in Upcoming Investor Conferences - May 23, 2024
2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences.
May 23, 2024
·
1 min read
Deals
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
2seventy bio, Inc., announced the completion of an asset purchase agreement by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.
June 26, 2024
·
4 min read
Business
2seventy bio Reports First Quarter 2024 Financial Results and Recent Operational Progress
2seventy bio, Inc., reported financial results and recent highlights for the first quarter ended March 31, 2024.
May 8, 2024
·
22 min read
Business
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.
May 3, 2024
·
1 min read
Genetown
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy bio, Inc., announced the completion of the asset purchase agreement by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
April 1, 2024
·
4 min read
1 of 83,574
Next